Search research articles
Contact Us
Filters
Showing results (451-460 of 484) with videos related to
Page
of 49
Sort By:
American Heart Journal
|
August 25, 2024
Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: Rationale and design of the CRAFT trial
Chao Jiang, Zhiyan Wang, Xin Du, et al.
Heart (British Cardiac Society)
|
June 30, 2018
Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials
Vanessa Selak, Ruth Webster, Sandrine Stepien, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
Circulation
|
October 21, 2016
Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus
Zahir H Alshehry, Piyushkumar A Mundra, Christopher K Barlow, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
Circulation
|
March 21, 2022
Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study
Ka-Chun Li, Liping Huang, Maoyi Tian, et al.
Lancet (London, England)
|
September 13, 2016
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins, Christina Reith, Jonathan Emberson, et al.
The New England Journal of Medicine
|
September 20, 2014
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Sophia Zoungas, John Chalmers, Bruce Neal, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Page
of 49
Search research articles
Search
Showing results (451-460 of 484) with videos related to
Sort By:
Page
of 49
American Heart Journal
|
August 25, 2024
Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: Rationale and design of the CRAFT trial
Chao Jiang, Zhiyan Wang, Xin Du, et al.
Heart (British Cardiac Society)
|
June 30, 2018
Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials
Vanessa Selak, Ruth Webster, Sandrine Stepien, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
Circulation
|
October 21, 2016
Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus
Zahir H Alshehry, Piyushkumar A Mundra, Christopher K Barlow, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
Circulation
|
March 21, 2022
Cost-Effectiveness of a Household Salt Substitution Intervention: Findings From 20 995 Participants of the Salt Substitute and Stroke Study
Ka-Chun Li, Liping Huang, Maoyi Tian, et al.
Lancet (London, England)
|
September 13, 2016
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins, Christina Reith, Jonathan Emberson, et al.
The New England Journal of Medicine
|
September 20, 2014
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Sophia Zoungas, John Chalmers, Bruce Neal, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
Page
of 49